With the development of new advances in hepatocellular carcinoma (HCC) management and noninvasive radiological techniques, high-risk patient groups such as those with hepatitis virus are closely monitored. HCC is increasingly diagnosed early, and treatment may be successful. In spite of this progress, most patients who undergo a hepatectomy will eventually relapse, and the outcomes of HCC patients remain unsatisfactory. In our study, we aimed to identify potential gene biomarkers based on RNA sequencing data to predict and improve HCC patient survival. 
outcomes and may also help improve survival forecasts. 2 However, traditional clinical information has a limited predictive power because of the complex molecular mechanisms of tumour regulation. Therefore, there is a strong need to explore new tools, such as molecular markers, to predict patient prognosis more accurately.
In this genomic era, a large number of genome-sequencing technologies and data have emerged. 3 These tools have made great contributions to tumour diagnosis and prognosis prediction. RNA sequencing is a recently developed deep-sequencing method that can recognize splice variants, unmapped genes and spliced unrecognized noncoding RNAs. Using the lung adenocarcinoma (LUAD) dataset of The Cancer Genome Atlas (TCGA), Anlin Feng et al 4 found
that the overall survival (OS) of LUAD patients with high HMGB1 expression was poor, demonstrating that these novel next-generation sequencing approaches and data can identify clinical biomarkers of cancer. Similarly, we predicted the prognosis of HCC patients using high-throughput sequencing of biomarkers.
In this study, we aimed to explore the difference in the mRNA expression profiles of HCC and the adjacent liver to identify potential gene biomarkers using TCGA data. We established a four-gene 
| MATERIALS AND METHODS

| Data source
The mRNA expression profiles and the corresponding clinical information from the patients with HCC were obtained from the TCGA, which was calculated on an Illumina HiSeq RNA-seq platform, containing 374 HCC tissues and 50 adjacent nontumourous liver tissues as of January 1, 2018 . The data from the TCGA are publicly available and open-access; therefore, the local ethics committees did not need to approve the study because the current research follows the TCGA data access policies and publication guidelines.
| Differentially expressed mRNA screening between HCC and noncancer tissues
First, we obtained the raw counts of the HCC mRNA expression profiles from the TCGA databases. The RNA sequencing data of HCC included 57 000 mRNA expression profiles. Then, the differentially expressed genes (DEGs) were calculated using the DESeq R package. The DEGs of the dataset with an absolute log2 fold change (FC) > 4 and an adjusted P value of <0.001 were considered for subsequent analysis.
| Definition of the gene-related prognostic model
Univariate, Lasso and multivariate Cox regression analyses were employed to investigate the correlation between patient OS and the expression level of each gene. The gene was considered significant when the P value was <0.001 in the univariate Cox regression analysis. Next, we applied a Lasso-penalized Cox regression to further reduce genes for patients with HCC. For the Lasso-penalized Cox regression selection operator, we subsampled the dataset with replacement 1000 times and selected the markers with repeat occurrence frequencies of more than 900. The tuning parameters were determined according to the expected generalization error estimated from 10-fold cross-validation and information-based criteria Akaike
Information Criterion/Bayesian Information Criterion (AIC/BIC), and we adopted the largest value of lambda such that the error was within one standard error of the minimum, called "1-se" lambda. optimal cut-off value was found using X-tile software. 5 Thresholds for the scores that were outputted from the prognostic model that were applied to classify patients into low-and high-risk groups were defined as the scores that yielded the largest χ² value in the MantelCox test. The 365 HCC patients with survival data were separated into low-and high-risk groups based on the optimal cut-off value.
The Kaplan-Meier (K-M) survival curves for the cases with a low or high risk were produced. Time-dependent receiver operating characteristic (ROC) curve analyses were conducted to evaluate the predictive power of the prediction model. Then, the prognostic model was validated in the GEO dataset (GSE54236). 
| Independence of the prognostic model from other clinical characteristics
| External validation of the expression patterns of the four genes
We also attempted to validate the expression patterns of the four genes in the TCGA; thus, the expression levels of these four mRNAs from GEO (GSE54236) were extracted for further analysis.
The differentially expressed patterns of the four genes between the HCC and nontumourous tissues were analysed in Prism 6.0 (GraphPad, San Diego, CA, USA) using the Wilcoxon signed-rank test. The P values are two-sided, and P < 0.05 indicates statistical significance.
| Building and validating a predictive nomogram
Nomograms are widely applied to predict cancer patients' prognoses, mainly because they can reduce the statistical prediction models into a single numerical assessment of the probability of OS that is tailored to the profile of an individual patient. 6 In this study, the com- Therefore, the DCA can decide whether the predictive nomogram is clinically useful or not. The best model is one with a high net benefit as calculated within the favourable probability.
| RESULTS
| Differentially expressed mRNAs between HCC and normal tissue
To describe our study more clearly, a flow chart of the analysis pro- However, age, AFP, sex, weight, inflammation, histologic grade and family history did not correlate with OS ( Figure 3 ; Table S1 ).
Considering that age almost reached statistical significance, we incorporated age, pathologic stage, vascular tumour invasion and the prognostic model into the multivariate Cox regression analysis. After the multivariate Cox regression analysis, the age, the pathologic stage and the prognostic model were independent prognostic factors associated with OS ( Figure 3 ; Table S1 ).
| Prediction condition of the prognostic model in the GEO dataset
To evaluate the predictive value of the prognostic model in predicting the OS for the patients with HCC in other datasets, the prognostic model was assessed in the GEO microarray data (GSE54236). 7 A total of 78 patients in the GSE54236 data were classified into a low-risk group (n = 59) and a high-risk group (n = 19) using the optimal risk cut-off value of the GEO data and the same risk score model of the TCGA data ( Figures S3B and S4B) . Consistent with the result in the TCGA, the OS of the HCC patients in the GSE54236 data in the high-risk group was significantly lower than that in the low-risk group (median survival: 0.99 years vs 2.26 years; P < 0.0001; Figure 2B ). The 3-year survival rates were 25% in lowrisk patients and 0% in high-risk patients. In addition, the time- Figure 3B ). The AUC at 5 years was not shown in Figure 2B because no patients in the GEO validation set survived for more than 5 years.
| Functional enrichment analysis
To elucidate the functional characteristics of the identified proteincoding genes, we performed enrichment analyses of the GO and KEGG pathways, which showed that a total of 1 GO term and 4 KEGG pathways were enriched by the four-gene signature (P < 0.05; Figure S5 ). The results showed that the genes were enriched in skeletal system development function and ECM-receptor interaction, the Toll-like receptor signalling pathway, focal adhesion and the PI3K-Akt signalling pathway.
| Validation of the expression of the four mRNAs
In the TCGA HCC cohort, all four genes were highly expressed in HCC compared with their expression in the adjacent nontumourous liver tissues ( Figure 4A ). To further confirm the expression patterns of the four genes in the GEO database, they were selected from GSE54236. The transcriptome profiling data in the GSE54236 dataset contained 78 patients, including 78 adjacent nontumour samples and 78 HCC samples. Consistent with our results, the mean expression levels of CENPA, SPP1 and HOXD9 were significantly higher than those of noncancerous liver tissues in the GEO database LONG ET AL.
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( Figure 4B ). However, due to the small size of the patients, no significant differences were found in MAGEB6 expression ( Figure 4B ). To determine the clinical relevance of the expression of the four genes,
we analysed the expression of the proteins encoded by the four genes using clinical specimens from the Human Protein Profiles (www.proteinatlas.org). 8 SPP1 was strongly positive in HCC and CENPA, and MAGEB6 was weakly positive in HCC, relative to their expression levels in normal liver tissue ( Figure 4C ). However, HOXD9 was not found on the website.
| Building and validating a predictive nomogram
To establish a clinically applicable method for predicting the survival probability of patients with HCC, we developed a nomogram to predict the probability of the 1-, 3-and 5-year OS in the TCGA cohort.
The predictors of the nomogram included three independent prognostic factors (age, pathologic stage and prognostic model; Figure 5A ). The C-index for the model for evaluation of OS was 0.69, with 1000 cycles of bootstrapping (95% confidence interval: (Table 1 ). The AUC of the nomogram was also the largest ( Figure 6A ). The clinical usefulness was assessed using DCA.
The nomogram showed the best net benefit ( Figure 6B ). These findings demonstrate that compared with nomograms built with a single prognostic factor, the nomogram built with the combined model is the best nomogram for predicting survival for patients with HCC, whether in the short or long term, which might facilitate patient counselling, decision-making and follow-up scheduling.
| DISCUSSION
HCC remains one of the deadliest malignant tumours worldwide because of its complicated molecular and cellular heterogeneity, and its incidence increases every year. 9 Therefore, understanding Therefore, high-risk groups should be followed more frequently, We also demonstrated that the prognostic model was independent of other clinical factors in HCC. The prognostic model was used to predict the GEO dataset (GSE54236) to test its predictive power, and the expression levels of the four genes were also validated.
Using the enrichment and functional analysis and the DAVID and KEGG bioinformatics tools, we found that the GO functions of the four genes were enriched in skeletal system development (P value <0.05), and the KEGG pathways were enriched in ECM-receptor interaction, the Toll-like receptor signalling pathway, focal adhesion and the PI3K-Akt signalling pathway.
A nomogram is a statistical tool that provides the individual patient with the overall probability of a particular outcome. In this study, we constructed a nomogram built with a combined model to The HOX gene family is a network of genes that encode DNA-binding proteins. 12 This family is highly conserved throughout the whole evolution process and is involved in many signal transduction pathways, such as cell development, migration and differentiation. 12, 13 HOXD9 is a member of the homeobox gene family. 14 HOXD9 showed high upregulation in invasive HCC cells.
The high expression of HOXD9 is related to the invasion, 
15
MAGEB6 belongs to the MAGEB gene family. 15 For all members of this gene family, the entire coding sequence is located in the last exon, and the sequence identity of encoded proteins reaches 50%-68%. 16, 17 Cancer-testis antigens (CTAs) are expressed in diverse histological types of malignant tumours, yet they are seldom expressed in normal somatic tissues except for immunoprivileged gametogenic tissues, which indicates a similarity between the gametogenesis and tumourigenesis processes. 18 CTAs exhibit a strong immunogenicity and a specific expression pattern, making them a promising target. 19 CTAs or peptides derived from CTAs can be used for cancer vaccination due to their immunogenicity. cancer. 23, 24 In HCC, a large number of CTA genes show validated expression at the RNA level, including members of the MAGE-A, MAGE-B, and MAGE-C families. 25 As of now, the best-characterized CTAs in HCC are the MAGE antigens. 26 In particular, up to 45%-52% of all HCCs express the MAGEB1 antigen, and up to 60%-62% of all HCCs express the MAGEB2 antigen. 26 However, the expression pattern of MAGEB6 in HCC has not previously been elucidated. In this study, we show for the first time that MAGEB6 is highly expressed in HCC based on RNA-seq data in the TCGA database, and its use in the prognostic model was found to independently predict the prognosis of patients with HCC, similar to its predictive utility in head and neck squamous cell carcinoma (HNSCC). MAGEB6 was found to be frequently expressed in HNSCC, and there is a clear association between MAGE6B mRNA positivity and recognized clinical characteristics of unfavourable prognosis, which suggests that MAGE6B may be an interesting target for HNSCC immunotherapy treatment. 27 Therefore, because
CTAs are capable of eliciting spontaneous antitumour immune responses, the CTA member MAGEB6 is a promising candidate 
